Besides possible therapeutic benefits of ATIII administration, the major finding of our investigation was the striking predictive potential of ATIII-activity for postoperative LD and clinical outcome in mCRC patients without underlying liver disease, as well as in a routine clinical setting of hepatic resections. Here, SERPINC1 is linked to liver disorder.